Rats with portacaval shunts and humans with hepatic encephalopathy show severe myo-inositol depletion in the brain. The portacaval-shunted rat may therefore be a useful model for the INTRODUCTION myo-Inositol, an intermediate in the cerebral inositol polyphosphate (IPP) cascade [1, 2] , is normally present at about 5 mM in the human brain and has recently been detected in noninvasive proton [3, 4] and "IC magnetic resonance (m.r.) spectra [5]. In humans, in vivo proton magnetic resonance spectroscopy (1H m.r.s.) of the brain shows that a significant increase in the myo-inositol content is a feature of Alzheimer's disease [6] and diabetes mellitus [7] and, in the neonatal brain, the myo-inositol concentration is 250 % of the normal adult level [8,9]. Conversely, a significant reduction in cerebral myo-inositol is observed in in vivo 'H m.r.s. in patients with chronic hepatic encephalopathy (HE) [10]. In Alzheimer's disease, it has been postulated that phosphatidylinositol depletion [11] and abnormalities in inositol phosphokinase activity [12] are part of a general neurochemical disturbance of the IPP pathway. An animal model for the study of the factors that modulate cerebral myo-inositol metabolism, therefore, is of interest. In the past, rats with portacaval shunts (PCS rats) have served as a model for HE in humans, but a deficiency in cerebral myo-inositol has not been reported [13, 14] in these animals.
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EXPERIMENTAL

Animals
Male rats (Sprague-Dawley), given free access to food and drink, and weighing 200-250 g, were used. The whole forebrains of ten PCS rats (Zivic Miller) and ten control rats, which had been anaesthetized with intraperitoneal Nembutal (50 mg/kg) and killed 6-8 weeks after surgery, were used in this study. Two additional controls were: (1) a PCS rat which had undergone surgery but in which the shunt had been closed before the animal was killed; and (2) a normal rat which underwent anaesthesia and surgery, but was then allowed to recover, until being killed 6 weeks later. To obtain the brain in as near an in vivo state as possible, animals were anaesthetized with intraperitoneal investigation of neurochemical pathways containing myoinositol, which are modulated not only in hepatic encephalopathy but also in diabetes mellitus and Alzheimer's disease. pentobarbitone and the skull was opened. The whole brain was rapidly excised and immersed in liquid nitrogen.
Patients
The brains from two cirrhotic patients who had died in hepatic coma and from three patients without liver disease who had died of pulmonary embolism, respiratory collapse and myocardial infarction respectively were obtained at autopsy. Samples from the frontal, parietal and occipital lobes were dissected, frozen in liquid nitrogen and stored at -70 'C. The interval from death of the subject to freezing of dissected autopsy material was between 12 and 24 h.
For both animal and patient studies, the weighed cerebral tissue was homogenized in 6 % perchloric acid, neutralized with 30 % KOH, but without addition of pH indicator, which interferes with both h.p.l.c. and m.r. assays, and passed through a Sep-Pak C18 cartridge (Millipore, Milford, MA, U.S.A.) H.p.l.c. was performed as described previously by Lien et al. [15] .
M.r.s.
'H m.r.s. was performed on rat and human brain HC104 extracts using a Bruker AMX-500 n.m.r. spectrometer. HC104 extracts were either directly analysed after the addition of 2H20 containing 5 mM 3-(trimethylsilyl)-1-propanesulphonic acid (DSS) or evaporated to dryness and dissolved in 2H20 containing 5 mM DSS. The acquisition, with presaturation to suppress the water resonance when needed, consisted of 128 scans with a 5.0 s relaxation delay and a 16 K data set. The data processing consisted of an exponential line-broadening of 0.05 Hz using the program Felix 2.05 (Hare Software, Inc.) with a baseline correction using a spline fitting procedure.
RESULTS
Figure 1(a) shows representative h.p.l.c. chromatograms of brain extracts from a PCS rat and a normal rat. The peak areas of myoinositol and glycerophosphocholine (GPC) were decreased, and that of glutamine was increased in the PCS rat compared with the control. In 10 PCS rats, myo-inositol and GPC decreased by an average of40 % and 33 % respectively, and the brain glutamine content increased by 98 The upper traces are of a PCS rat (a) and a hepatic coma patient (b); their respective controls. The peaks of myoinositol (Ml), taurine (Ta glutamate (Glu), glycine (Gly) and creatine (Cr) are indicated.
(P < 0.01) ( Table 1 ). The elevation of cerebral glutamine is well known from prior work [16] . Concentrations of other metabolites, including taurine, urea, creatine and glutamate, were not statistically different between the two groups. In the surgical controls (n = 2), metabolite concentrations were indistinguishable from those in the normal rats. In particular, myo-inositol and glutamine were within the normal range (first control: Gln = 5.62 mM, GPC = 0.69 mM, myo-inositol = 5.31 mM; second control: Gln = 3.58 mM, GPC = 0.47 mM, myoinositol = 5.40 mM).
Figure l(b) shows representative h.p.l.c. chromatograms of human brain extracts from a patient with hepatic coma and a control patient. In patients with hepatic coma, the peak areas of myo-inositol and GPC were decreased, and that of glutamine was increased compared with the control. The peak areas of taurine, urea and creatine were also increased in the hepatic coma patients (not confirmed by m.r.s. Figure 2(a) . In addition to the dramatic increase in glutamine peak areas, the choline region and myo-inositol peaks were decreased in PCS rats compared brain extracts from with controls. The 1H m.r. spectra from the occipital lobe of an HE patient and a 'control' are distinguished by decreased myothe lower traces are from inositol peaks, a decrease in the choline region and an increase in u), GPC, glutamine (Gln), glutamine peaks (Figure 2b ). Because the occipital cortex is a location that we have analysed by in vivo IH m.r.s. in chronic HE patients, these spectra directly confirm our in vivo results.
DISCUSSION
The role of myo-inositol in the central nervous system is rather complex. First, myo-inositol is the precursor of IPPs, which are important secondary messengers involved in a large number of hormonal systems in the central nervous system [17] . Secondly, myo-inositol content in nerve cells is related to sodium pump activity and nerve conduction velocity, as shown in diabetic peripheral neuropathy [18] . myo-Inositol depletion may contribute to the neurological manifestation of HE. In human subjects, myo-inositol depletion is reversed by liver transplantation [10] , and neurological status is also improved.
The mechanisms of myo-inositol depletion in patients with chronic HE, or in PCS rats, are largely unknown. myo-Inositol can be synthesized in the brain from glucose or transported into the brain via specific transporters [19, 20] . In HE, hyperammonaemia is associated with decreased glucose utilization in the brain [21] , and may therefore cause myo-inositol depletion by reducing myo-inositol synthesis. Alternatively, since myo-inositol is the precursor of glucuronic acid via myo-inositol oxygenase, its The lower spectra are of a PCS rat (a) and the occipital lobe of a hepatic coma patient (b); the upper spectra are their respective controls. The extracts are the same as those described in the legend to Figure 1 (five PCS rats and five controls were used in the m.r.s. study). Resonances of myo-inositol (ml), taurine (Tau); choline region (Cho; which includes choline, GPC and diglycerophosphocholine), glutamine (Gln), glutamate (Glu), glycine (Gly), creatine (Cr) and scy/i-inositol (sl) are indicated. NAA, Nacetylaspartate. (a) The spectra are plotted by normalizing the intensity of the Cr peak at 3.02 p.p.m. with a small correction needed to compensate for extract dilution factors. (b) The spectra are plotted by normalizing the intensity of the peak at 2.9 p.p.m. and correction for extract dilution factors. Note the separation of the glycine and myo-inositol resonances, with the area of the relatively small glycine singlet clearly only slightly decreased in the patient compared with the control, and therefore this cannot be responsible for the decrease in this region observed in the in vivo spectra of HE patients.
depletion might be the result of the excessive cerebral detoxification that is necessary in patients or experimental animals with long-term portasystemic shunts. This hypothesis also implies that myo-inositol depletion contributes to the observed sensitization of the brain to other neurotoxins in HE. Because both glutamine and myo-inositol can be viewed as contributing to intracellular osmotic pressure, the reduced myo-inositol concentration might simply result from the increased intracellular osmolarity due to accumulation of glutamine observed in the presence of hyperammonaemia [15] . Such a simple explanation was considered unlikely in the setting of human HE (see Fig. 5 in ref.
[10]). In Alzheimer's disease, the concomitant alteration in inositol phosphokinase and depletion of inositol phosphate may indicate altered regulation of the biosynthetic pathway of myoinositol.
We have demonstrated cerebral myo-inositol and GPC depletion in both PCS rats and patients with hepatic coma. These findings are consistent with our previous in vivo m.r.s. studies in patients with chronic HE. Any hypothesis for the pathogenesis of HE must take into account this decrease in myo-inositol. The PCS rat model can be used to explore the role of myo-inositol (and IPPs) in neurology and, while we do not suggest any aetiological link between Alzheimer's disease and chronic HE, it may also provide a model for pharmacological manipulation that targets myo-inositol in Alzheimer's disease [6] .
